Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8349717 | Pharmacological Reports | 2018 | 13 Pages |
Abstract
C-Phycocyanin (C-PC) has been shown to be promising in cancer treatment; however, although several articles detailing this have been published, its main mechanisms of action and its cellular targets have not yet been defined, nor has a detailed exploration been conducted of its role in the resistance of cancer cells to chemotherapy, rendering clinical use impossible. From our extensive examination of the literature, we have determined as our main hypothesis that C-PC has no one specific target, but rather acts on the membrane, cytoplasm, and nucleus with diverse mechanisms of action. We highlight the cell targets with which C-PC interacts (the MDR1 gene, cytoskeleton proteins, and COX-2 enzyme) that make it capable of killing cells resistant to chemotherapy. We also propose future analyses of the interaction between C-PC and drug extrusion proteins, such as ABCB1 and ABCC1, using in silico and in vitro studies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Estela Fernandes e Silva, Felipe da Silva Figueira, Aline Portantiolo Lettnin, Michele Carrett-Dias, Daza de Moraes Vaz Batista Filgueira, Susana Kalil, Gilma Santos Trindade, Ana Paula de Souza Votto,